ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.